Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Sinovac Files to Start Trial of Bacterial Vaccine

publication date: Jan 31, 2011
Sinovac Biotech submitted a request to the SFDA to conduct a clinical trial of its newly developed 23-valent and 24-valent pneumococcal polysaccharides vaccines (PPV). The vaccines are designed to protect against pneumonia, meningitis and febrile bacteremia along with sinusitis and bronchitis. The target populations are children over the age of two and adults, especially those older than 65 and those with long-term health problems. More details....

Stock Symbol: (NSDQ: SVA)


Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here